Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 28 04:00PM ET
6.71
Dollar change
+0.43
Percentage change
6.85
%
IndexRUT P/E- EPS (ttm)-2.35 Insider Own56.51% Shs Outstand42.28M Perf Week2.13%
Market Cap285.64M Forward P/E- EPS next Y-1.29 Insider Trans-0.05% Shs Float18.51M Perf Month-13.75%
Income-98.43M PEG- EPS next Q-0.62 Inst Own30.67% Short Float6.77% Perf Quarter0.60%
Sales34.16M P/S8.36 EPS this Y11.11% Inst Trans-0.31% Short Ratio7.50 Perf Half Y12.02%
Book/sh-1.83 P/B- EPS next Y37.79% ROA-28.50% Short Interest1.25M Perf Year17.51%
Cash/sh5.50 P/C1.22 EPS next 5Y- ROE-470.38% 52W Range2.70 - 9.97 Perf YTD4.03%
Dividend Est.- P/FCF- EPS past 5Y-26.80% ROI- 52W High-32.70% Beta3.12
Dividend TTM- Quick Ratio4.11 Sales past 5Y328.43% Gross Margin82.61% 52W Low148.52% ATR (14)0.62
Dividend Ex-Date- Current Ratio4.11 EPS Y/Y TTM10.40% Oper. Margin-315.93% RSI (14)55.64 Volatility7.64% 10.00%
Employees116 Debt/Eq- Sales Y/Y TTM77.63% Profit Margin-288.17% Recom1.00 Target Price16.33
Option/ShortYes / Yes LT Debt/Eq- EPS Q/Q17.50% Payout- Rel Volume0.41 Prev Close6.28
Sales Surprise26.90% EPS Surprise23.39% Sales Q/Q37.88% EarningsMar 07 BMO Avg Volume167.14K Price6.71
SMA202.57% SMA5021.92% SMA20011.14% Trades Volume68,593 Change6.85%
Date Action Analyst Rating Change Price Target Change
Mar-28-23Initiated BofA Securities Buy $10
Jan-05-23Initiated BMO Capital Markets Outperform $20
Nov-22-21Initiated H.C. Wainwright Buy $25
Nov-17-20Initiated Wedbush Outperform $24
Nov-17-20Initiated Morgan Stanley Overweight $24
Nov-17-20Initiated Goldman Buy $27
Nov-17-20Initiated Cowen Outperform
Mar-26-24 07:00AM
Mar-19-24 08:30AM
Mar-13-24 12:00PM
09:55AM
Mar-07-24 02:52PM
08:20AM Loading…
08:20AM
07:00AM
Mar-05-24 04:48PM
Feb-28-24 07:00AM
Feb-12-24 02:43AM
Feb-09-24 10:02AM
Feb-08-24 07:00AM
Jan-09-24 08:44AM
Jan-08-24 07:00AM
06:30AM
06:30AM Loading…
06:30AM
Jan-03-24 04:05PM
Dec-26-23 12:00PM
Dec-11-23 09:55AM
Dec-01-23 07:00AM
Nov-27-23 07:01PM
Nov-21-23 06:00AM
Nov-03-23 06:12AM
Nov-02-23 07:00AM
Nov-01-23 10:30AM
Oct-24-23 08:00AM
Oct-19-23 10:30AM
Oct-13-23 08:00AM
Oct-04-23 08:00AM
Oct-02-23 07:00AM
08:31AM Loading…
Sep-27-23 08:31AM
Sep-11-23 06:30AM
Sep-05-23 08:00AM
Aug-31-23 07:00AM
Aug-29-23 09:00AM
Aug-11-23 03:54PM
Aug-08-23 07:00AM
Aug-04-23 08:15AM
07:00AM
Jul-09-23 07:58PM
Jun-28-23 01:44PM
07:00AM
Jun-07-23 08:00AM
Jun-06-23 07:56AM
Jun-05-23 07:00AM
May-16-23 06:00AM
May-10-23 07:47AM
May-08-23 08:15AM
07:00AM
Apr-27-23 04:35AM
Apr-25-23 04:05PM
Apr-24-23 01:28PM
07:46AM
07:00AM
Apr-10-23 04:05PM
03:20AM
Apr-06-23 04:05PM
Mar-26-23 08:14AM
Mar-09-23 08:35AM
07:00AM
Mar-01-23 08:00AM
Feb-16-23 01:49PM
Jan-09-23 07:00AM
Dec-21-22 05:19AM
Dec-05-22 07:00AM
Nov-22-22 08:00AM
Nov-14-22 07:00AM
Nov-10-22 05:18AM
Nov-09-22 07:00AM
Nov-08-22 08:15AM
07:00AM
Oct-27-22 07:00AM
Oct-26-22 09:55AM
07:00AM
Oct-20-22 07:00AM
Oct-16-22 10:45AM
Sep-27-22 08:00AM
Sep-01-22 04:05PM
Aug-31-22 04:05PM
Aug-25-22 06:27AM
Aug-24-22 09:57AM
Aug-23-22 11:31AM
07:59AM
07:00AM
Aug-17-22 07:00AM
Aug-09-22 08:25AM
07:00AM
Aug-01-22 08:00AM
Jun-23-22 07:41AM
May-31-22 04:05PM
May-26-22 11:03AM
May-20-22 11:51AM
08:15AM
06:25AM
May-19-22 04:01PM
May-09-22 07:00AM
06:52AM
Apr-13-22 11:30AM
Apr-01-22 08:00AM
Mar-23-22 07:46AM
Foghorn Therapeutics, Inc. operates as a development stage biopharmaceutical company. It is discovering and developing a novel class of precision medicine therapeutics targeting the chromatin regulatory system in oncology. Through its scalable Gene Traffic Control product platform, the firm is systematically interrogating and drugging the chromatin regulatory system. The company was founded by Cigall Kadoch, Gerald W. Crabtree and Douglas G. Cole in October 2015 and is headquartered in Cambridge, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Cavalie FannyChief Strategy/Bus Ops OfficerMar 11 '24Sale6.5611,00072,13475,992Mar 12 04:19 PM
Agresta SamuelChief Medical OfficerAug 16 '23Option Exercise3.72311,2971,158,025311,297Aug 18 04:03 PM
Agresta SamuelChief Medical OfficerAug 16 '23Sale8.25311,2972,568,2000Aug 18 04:03 PM